<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82719">
  <stage>Registered</stage>
  <submitdate>3/04/2008</submitdate>
  <approvaldate>8/04/2008</approvaldate>
  <actrnumber>ACTRN12608000170325</actrnumber>
  <trial_identification>
    <studytitle>A Study to Assess the Effect of changing testosterone levels on quality of life and physiology in men with prostate cancer undergoing hormone therapy</studytitle>
    <scientifictitle>A Phase II Study to Assess the Effect of Intermittent Androgen Blockade in the Treatment of Advanced Prostate Cancer</scientifictitle>
    <utrn />
    <trialacronym>GUOG IAB study</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intermittant androgen suppression. Flutamide (Eulexin) 250 mg three times a day and Leuprolide (Lucrin) 22.5 mg three monthly depot for 9 months (this is the treatment phase), at which point patients cease therapy and remain off therapy providing prostate specific antigen (PSA) &lt; 4 ng/mL. Further androgen suppression treatment as above recommenced when the PSA exceeded 20 ng/mL or greater than pretreatment PSA if that was lower.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Quality of life - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) + Prostate Module and physiological measures: Full blood count, serum lipids, waist and hip measures, weight, bone turnover markers, Dual Energy X-ray Absorptiometry (DEXA) bone densitometry, fat assessment from DEXA scan, muscle strength by timed stands, lean mass from DEXA scan, Blood pressure (BP), and pulse.</outcome>
      <timepoint>Descriptive observational study over 3 years, with assessment 3 monthly. Effect on quality of life at each time point, with BP, weight, hip and waist measures, weight, timed stands, disease activity measured at each time point, DEXA scan assessments at baseline, end of treatment phase (9 months) then at 1 and 2 yeasr after. Bone activity measures at baseline, during treatement and post treatment period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None.</outcome>
      <timepoint>None.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Prostate cancer requiring commencement of androgen suppression, and likely to be a candidate for an intermittant program.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior treatment with hormonal therapy, chemotherapy or biologic response modifiers (other than neoadjuvant hormonal therapy that meets the criteria  of 3.1.(i)
	b)  Patients presenting with acute or impending cord compression.
	c)  Patients with extensive involvement manifest by a report of superscan type uptake pattern.
	d)  History of prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, or other cancer for which the patient has been disease-free for at least 5 years.
e)  Patients with known history of hypersensitivity reaction to either study medication or drugs with a similar structure.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/05/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott pharmaceuticals Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Abbot Pharmaceuticals Pty Ltd
32-34 Lord Street
Botany NSW 1455</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Abbott pharmaceuticals Pty Ltd</fundingname>
      <fundingaddress>Abbott Australasia Pty Ltd
Abbot Pharmaceuticals Pty Ltd
32-34 Lord Street
Botany NSW 1455</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering Plough Pty Ltd</fundingname>
      <fundingaddress>Schering-Plough Pty Ltd
Level 4
66 Waterloo Road
North Ryde NSW 2113
Telephone: +61 2 89888000
Facsimile: +61 2 8988800</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Schering Plough Pty Ltd</sponsorname>
      <sponsoraddress>Schering-Plough Pty Ltd
Level 4
66 Waterloo Road
North Ryde NSW 2113
Telephone: +61 2 89888000
Facsimile: +61 2 8988800</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Genito Urinary Oncology Group, NSW.</othercollaboratorname>
      <othercollaboratoraddress>Dr Andrew Kneebone 
Secretary
Genito Urinary Oncology Group, NSW
Cancer Centre
Elizabeth Street
Liverpool BC NSW 1871</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>1.1	To identify the variation in health related quality of life (HQOL) of patients with advanced prostate cancer treated with intermittent maximal androgen blockade therapy (IMAB).
1.2	To observe the effects of intermittent androgen blockade therapy on the rate and extent of androgen dependent physiological parameters as well as noting serial side effects and patient compliance with the treatment program.
1.3	To gain information regarding time to disease progression and overall survival of patients with advanced prostate cancer treated with intermittent maximal androgen blockade therapy.
1.4	To quantify the relative and absolute amounts of time achieved off treatment from the commencement of active therapy</summary>
    <trialwebsite>None</trialwebsite>
    <publication>Longitudinal Quality of Life (QOL) study of Australian men following intermittent maximal androgen blockade for prostate cancer using the EORTC QLQ-C30 + Prostate 26 module
SPRY N.A., Kristjanson L., Hooton B., Hayden L., Neerhut G., Gurney H., Corica T., Korbel E., Weinstein S., McCaul K.  Eur J Cancer 42: (6) 1083-92, 2006 
galvao changes in muscle and fat, iab study can exercise ameliorate the side effects of ast
3.	International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1443 patients.
Shaw G, Wilson P, Cuzick J, Prowse D, Goldenberg SL, SPRY N, Oliver RTD BJU Int. 2007 May;99(5):1056-65. Epub 2007 Mar 6. 
2.	International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1443 patients.
Shaw G, Wilson P, Cuzick J, Prowse D, Goldenberg SL, SPRY N, Oliver RTD
BJU Int. 2007 May;99(5):1056-65. Epub 2007 Mar 6.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress>Verdun Street
Nedlands Perth WA 6009</ethicaddress>
      <ethicapprovaldate>17/05/1999</ethicapprovaldate>
      <hrec>99-040</hrec>
      <ethicsubmitdate>19/04/1999</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Nigel Spry</name>
      <address>Sir Charles Gairdner Hospital
Block F
Verdun Street
Nedlands WA 6009</address>
      <phone>+61 8 93464900</phone>
      <fax />
      <email>Jonathan.Gopal@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Nigel Spry</name>
      <address>Sir Charles Gairdner Hospital
Block F
Verdun Street
Nedlands WA 6009</address>
      <phone>+61 8 93464900</phone>
      <fax />
      <email>Jonathan.Gopal@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Nigel Spry</name>
      <address>Sir Charles Gairdner Hospital
Block F
Verdun Street
Nedlands WA 6009</address>
      <phone>+61 8 93464900</phone>
      <fax />
      <email>Jonathan.Gopal@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>